-
For today's top Money video click here - News Providers
- Associated Press
- Barron's
- bizjournals.com
- Briefing.com
- BusinessWeek
- Business Wire
- Forbes
- GlobeNewswire
- InvestorPlace
- MarketWatch
- Market Wire
- Minyanville
- Motley Fool
- MSNBC
- PRNewswire
- Thomson Reuters
- TheStreet.com
- Wall Street Journal
- News by Topic
- Companies
- Economy
- Industry
- Stock Market
- Commentary
- This Week
- Index
- MSN Money Experts
- Jim Jubak
- Jon Markman
- Liz Pulliam Weston
- MP Dunleavey
- More Experts
3M announces drug licensing dealNovember 9, 2009 12:04 PM ETMitch Anderson 3M Co.’s drug-delivery unit has licensed some of its technology to vaccine developer VaxInnate Corp., the company said Monday. 3M Drug Delivery Systems said the deal with Cranbury, N.J.-based VaxInnate involves a 3M toll-like receptor (TLR) agonist, a drug that the company says has shown promise as vaccine adjuvants — additives that increase vaccine potency or efficiency. Under the terms of the non-exclusive licensing agreement, 3M provides its TLR agonists to VaxInnate for an undisclosed licensing fee, in addition to milestone and royalty payments. 3M said it continues to seek other licensing partners for the drug technology. Copyright 2009 bizjournals.com
|
E-mail this article
Print-friendly version
Discuss this article
- Data providers
- Copyright © 2010 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.